Literature DB >> 23454900

Molecular dissection of microsatellite instable colorectal cancer.

Eduardo Vilar1, Josep Tabernero.   

Abstract

UNLABELLED: Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a hereditary and sporadic basis, is linked to a clear clinicopathologic profile, and has prognostic implications. Inconclusive predictive data along with a paucity of targeted drug development have prevented this molecular classification system from being implemented in the clinical setting. New high-throughput genomic data have validated it, thus stressing the fact that it is ready to be applied clinically. SIGNIFICANCE: Application of a molecular classification of colorectal cancer in the clinical arena is an unmet promise. Recent results of large-scale genomic analyses have provided confirmation and further insights into the molecular biology of already known colorectal cancer subgroups. The quintessential example is the microsatellite instability subgroup, which has been well characterized during the past 2 decades. Future drug development and clinical research initiatives in colorectal oncology should consider these and other known cancer subgroups and start targeting these selected patient populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454900      PMCID: PMC3651752          DOI: 10.1158/2159-8290.CD-12-0471

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  72 in total

1.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

Authors:  R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

Review 2.  Molecular genetics of colorectal cancer.

Authors:  Eric R Fearon
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 3.  Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability.

Authors:  Alex Duval; Richard Hamelin
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

4.  The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.

Authors:  S Jacob; M Aguado; D Fallik; F Praz
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

5.  Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability.

Authors:  Y Mori; J Yin; A Rashid; B A Leggett; J Young; L Simms; P M Kuehl; P Langenberg; S J Meltzer; O C Stine
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.

Authors:  Roberta Magrini; Mandar R Bhonde; Marie-Luise Hanski; Michael Notter; Hans Scherübl; C Richard Boland; Martin Zeitz; Christoph Hanski
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

7.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

8.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

Authors:  Harith Rajagopalan; Alberto Bardelli; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

9.  Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.

Authors:  David Fallik; Francesco Borrini; Valérie Boige; Jérôme Viguier; Sandrine Jacob; Catherine Miquel; Jean-Christophe Sabourin; Michel Ducreux; Françoise Praz
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.

Authors:  Sarah A Martin; Madeleine Hewish; David Sims; Christopher J Lord; Alan Ashworth
Journal:  Cancer Res       Date:  2011-01-17       Impact factor: 12.701

View more
  43 in total

1.  DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.

Authors:  Nicole de Rosa; Miguel A Rodriguez-Bigas; George J Chang; Jula Veerapong; Ester Borras; Sunil Krishnan; Brian Bednarski; Craig A Messick; John M Skibber; Barry W Feig; Patrick M Lynch; Eduardo Vilar; Y Nancy You
Journal:  J Clin Oncol       Date:  2016-07-18       Impact factor: 44.544

2.  Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers.

Authors:  Nathália C Campanella; Gustavo N Berardinelli; Cristovam Scapulatempo-Neto; Danilo Viana; Edenir I Palmero; Rui Pereira; Rui M Reis
Journal:  Eur J Hum Genet       Date:  2013-11-06       Impact factor: 4.246

3.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

4.  Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.

Authors:  Minoru Koi; Melissa Garcia; Chan Choi; Hyeong-Rok Kim; Junichi Koike; Hiromichi Hemmi; Takeshi Nagasaka; Yoshinaga Okugawa; Yuji Toiyama; Takahito Kitajima; Hiroki Imaoka; Masato Kusunoki; Yin-Hsiu Chen; Bhramar Mukherjee; C Richard Boland; John M Carethers
Journal:  Gastroenterology       Date:  2016-01-02       Impact factor: 22.682

5.  Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Authors:  K Chang; J A Willis; J Reumers; M W Taggart; F A San Lucas; S Thirumurthi; P Kanth; D A Delker; C H Hagedorn; P M Lynch; L M Ellis; E T Hawk; P A Scheet; S Kopetz; J Arts; J Guinney; R Dienstmann; E Vilar
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

6.  Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer.

Authors:  Eduardo Vilar; Maureen E Mork; Amanda Cuddy; Ester Borras; Sarah A Bannon; Melissa W Taggart; Jun Ying; Russell R Broaddus; Rajyalakshmi Luthra; Miguel A Rodriguez-Bigas; Patrick M Lynch; Yi-Qian Nancy You
Journal:  Cancer Genet       Date:  2014-10-13

Review 7.  Genetics of rectal cancer and novel therapies: primer for radiologists.

Authors:  Sebastian Mondaca; Rona Yaeger
Journal:  Abdom Radiol (NY)       Date:  2019-11

8.  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

Authors:  J Goldstein; B Tran; J Ensor; P Gibbs; H L Wong; S F Wong; E Vilar; J Tie; R Broaddus; S Kopetz; J Desai; M J Overman
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

Review 9.  Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.

Authors:  Sean M Ronnekleiv-Kelly; Richard A Burkhart; Timothy M Pawlik
Journal:  Surg Oncol       Date:  2016-05-20       Impact factor: 3.279

Review 10.  Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms.

Authors:  Laura Novellasdemunt; Pedro Antas; Vivian S W Li
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-19       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.